Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Melanoma 1Hematologic Neoplasms 1Coronavirus Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

Surveys and Questionnaires 6Standard of Care 6Blood Specimen Collection 6BNT162 Vaccine 5Hydroxychloroquine 4Surgical Procedures, Operative 3Specimen Handling 3Practice Guidelines as Topic 3COVID-19 Vaccines 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2Pandemic Preparedness 2CVnCoV COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1cilgavimab and tixagevimab drug combination 1ciclesonide 1avdoralimab 1XAV-19 1Therapeutics 1Telemedicine 1Sperm Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × COVID-19 × HuMax-IL8 × Clear all
NCT04347226 2025-05-22

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Columbia University

Phase 2 Terminated
43 enrolled 14 charts
Other hematologic neoplasm

COVID-19, Coronavirus Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡